Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

Breast cancer susceptibility gene 1 (BRCA1) located at chromosome 17q12-21 is a classic tumor suppressor gene, and has been considered as a significant role in hereditary breast cancers. Moreover, numerous studies demonstrated the methylation status of CpG islands in the promoter regions of BRCA1 gene was aberrant in patients with sporadic breast tumors compared with healthy females or patients with benign diseases. However, these conclusions were not always consistent. Hence, a meta-analysis was performed to get a more precise estimate for these associations. Crude odds ratio with 95% confidence interval were used to assess the association of BRCA1 promoter methylation and the risk or clinicopathologic characteristics of breast cancers under fixed or random effect model. A total of 40 studies were eligible for this present study. We observed the frequency of BRCA1 promoter methylation was statistically significant higher in breast cancers than non-cancer controls. Furthermore, BRCA1 methylation was statistically associated with lymph node metastasis, histological grade 3, ER(-), PR(-), triple-negative phenotype, and decreased or lack levels of BRCA1 protein expression. In conclusion, this study indicated that BRCA1 promoter methylation appeared to be a useful predictive or prognostic biomarker for breast cancers in clinical assessment.

[1]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[2]  C. Lopes,et al.  Detection of gene promoter hypermethylation in fine needle washings from breast lesions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[4]  E. Jung,et al.  Comparison of Methylation Profiling in Cancerous and Their Corresponding Normal Tissues from Korean Patients with Breast Cancer , 2013, Annals of laboratory medicine.

[5]  E. Biskup,et al.  Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells , 2014, Tumor Biology.

[6]  T. Nakajima,et al.  BRCA1 Expression Status in Relation to DNA Methylation of the BRCA1 Promoter Region in Sporadic Breast Cancers , 2000, Japanese journal of cancer research : Gann.

[7]  H. S. Shukla,et al.  Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population , 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[8]  M. Esteller,et al.  BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer , 2012, Epigenetics.

[9]  R. Bracci,et al.  BRCA1 expression in triple negative sporadic breast cancers. , 2010, Analytical and quantitative cytology and histology.

[10]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[11]  L. Chow,et al.  Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer , 1999, Oncogene.

[12]  Tim Hui-Ming Huang,et al.  Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. , 2003, The American journal of pathology.

[13]  X. Liu,et al.  Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[14]  J. Herman,et al.  BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[16]  A. Jakubowska,et al.  Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer , 2014, Breast Cancer Research and Treatment.

[17]  M. Hou,et al.  Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer , 2013, PloS one.

[18]  A. Toland,et al.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.

[19]  A. Neugut,et al.  BRCA1 promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[20]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[21]  A. Roessner,et al.  BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC , 2013, Breast Cancer Research and Treatment.

[22]  K. Amara,et al.  Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. , 2012, Cancer epidemiology.

[23]  Yuntao Xie,et al.  BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer , 2009, Cancer science.

[24]  G. Cao,et al.  Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. , 2012, Cancer epidemiology.

[25]  Graham G. Giles,et al.  Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.

[26]  A. Bal,et al.  BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression , 2012, Virchows Archiv.

[27]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[28]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[29]  M. Esteller,et al.  CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer , 2011, Epigenetics.

[30]  D. Seripa,et al.  Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors , 2004, Clinical Cancer Research.

[31]  S. Mirza,et al.  Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. , 2010, Life sciences.

[32]  A. Neugut,et al.  Gene promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[33]  E. Tokunaga,et al.  Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. , 2015, Clinical breast cancer.

[34]  G. Romieu,et al.  BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer , 2013, BMC Cancer.

[35]  M. Srinivasulu,et al.  Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue. , 2009, Cancer biomarkers : section A of Disease markers.

[36]  P. Toniolo,et al.  Methylation signature of lymph node metastases in breast cancer patients , 2012, BMC Cancer.

[37]  G. Shafi,et al.  Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer , 2013, Clinical and Translational Oncology.

[38]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[39]  H. Tsuda,et al.  Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. , 2002, Japanese journal of clinical oncology.

[40]  J. Jónasson,et al.  Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer , 2006, Breast Cancer Research.

[41]  W. Yuping,et al.  CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma , 2010, Tumor Biology.

[42]  Cheng Lu,et al.  Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis , 2013, Breast Cancer Research and Treatment.

[43]  S. Narod,et al.  Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Matthias W. Beckmann,et al.  Hereditary breast and ovarian cancer: review and future perspectives , 2005, Journal of Molecular Medicine.

[45]  R. Ziegler,et al.  Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls , 2012, Epigenetics.

[46]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[47]  Y. Bignon,et al.  BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. , 2012, Cancer epidemiology.

[48]  Tsuyoshi Saito,et al.  Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal‐like breast cancer , 2013, Histopathology.

[49]  Young-Man Cho,et al.  Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[50]  S. Noguchi,et al.  BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer , 2014, Cancer science.

[51]  A. Aboussekhra,et al.  Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women. , 2011, International journal of oncology.

[52]  N. Dalay,et al.  Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. , 2010, Anticancer research.

[53]  Jan Budczies,et al.  Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes , 2016, International journal of cancer.

[54]  T. Taguchi,et al.  BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation , 2011, Breast Cancer Research and Treatment.

[55]  N. Dalay,et al.  Methylation Profiles in Breast Cancer , 2009, Cancer investigation.

[56]  O. Olopade,et al.  BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. , 2005, Cancer research.

[57]  Li-hua Hu,et al.  Multigene Methylation in Serum of Sporadic Chinese Female Breast Cancer Patients as a Prognostic Biomarker , 2008, Oncology.